150 related articles for article (PubMed ID: 38696116)
1. Changes in metabolic parameters and serum YKL-40 levels in Chinese rheumatoid arthritis patients during tocilizumab therapy.
Hu W; Ding Y; Guan K; Zhang P; Su J; Zhang C; Li W; Lian C; Yang Q; Liu S; Li T
Clin Rheumatol; 2024 Jun; 43(6):1845-1853. PubMed ID: 38696116
[TBL] [Abstract][Full Text] [Related]
2. Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study.
Drobinski PJ; Bay-Jensen AC; Karsdal MA; Sardar S; Siebuhr AS
Arthritis Res Ther; 2021 Jan; 23(1):13. PubMed ID: 33413588
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Blanco R; Kadva A; Dimonaco S
Ann Rheum Dis; 2017 Jul; 76(7):1279-1284. PubMed ID: 28389552
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study.
Pablos JL; Navarro F; Blanco FJ; Román-Ivorra JA; Alonso A; Martín Mola E; Cantalejo M; Ercole L; Rivero N;
Clin Exp Rheumatol; 2019; 37(3):437-444. PubMed ID: 30299241
[TBL] [Abstract][Full Text] [Related]
6. Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis.
Ormseth MJ; Yancey PG; Solus JF; Bridges SL; Curtis JR; Linton MF; Fazio S; Davies SS; Roberts LJ; Vickers KC; Kon V; Michael Stein C;
Arthritis Rheumatol; 2016 Sep; 68(9):2099-105. PubMed ID: 26991245
[TBL] [Abstract][Full Text] [Related]
7. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA).
Bingham CO; Rizzo W; Kivitz A; Hassanali A; Upmanyu R; Klearman M
Ann Rheum Dis; 2015 May; 74(5):818-22. PubMed ID: 24448345
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction.
Smolen JS; Avila JC; Aletaha D
Ann Rheum Dis; 2012 May; 71(5):687-93. PubMed ID: 22121130
[TBL] [Abstract][Full Text] [Related]
9. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study.
McInnes IB; Thompson L; Giles JT; Bathon JM; Salmon JE; Beaulieu AD; Codding CE; Carlson TH; Delles C; Lee JS; Sattar N
Ann Rheum Dis; 2015 Apr; 74(4):694-702. PubMed ID: 24368514
[TBL] [Abstract][Full Text] [Related]
10. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.
Garnero P; Thompson E; Woodworth T; Smolen JS
Arthritis Rheum; 2010 Jan; 62(1):33-43. PubMed ID: 20039425
[TBL] [Abstract][Full Text] [Related]
11. Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis.
Murota A; Suzuki K; Kassai Y; Miyazaki T; Morita R; Kondo Y; Takeshita M; Niki Y; Yoshimura A; Takeuchi T
Cytokine; 2016 Feb; 78():87-93. PubMed ID: 26700586
[TBL] [Abstract][Full Text] [Related]
12. Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis.
Hoffman E; Rahat MA; Feld J; Elias M; Rosner I; Kaly L; Lavie I; Gazitt T; Zisman D
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540528
[TBL] [Abstract][Full Text] [Related]
13. Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment.
Cacciapaglia F; Anelli MG; Rinaldi A; Fornaro M; Lopalco G; Scioscia C; Lapadula G; Iannone F
Mediators Inflamm; 2018; 2018():2453265. PubMed ID: 30405318
[TBL] [Abstract][Full Text] [Related]
14. Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy.
Peterfy C; Kremer J; Rigby W; Singer N; Birchwood C; Gill D; Reiss W; Pei J; Michalska M
J Rheumatol; 2020 Mar; 47(3):325-332. PubMed ID: 31154414
[TBL] [Abstract][Full Text] [Related]
15. Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial.
Kremer JM; Rigby W; Singer NG; Birchwood C; Gill D; Reiss W; Pei J; Michalska M
Arthritis Rheumatol; 2018 Aug; 70(8):1200-1208. PubMed ID: 29575803
[TBL] [Abstract][Full Text] [Related]
16. Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab.
Shafran IH; Alasti F; Smolen JS; Aletaha D
Ann Rheum Dis; 2020 Jul; 79(7):874-882. PubMed ID: 32371387
[TBL] [Abstract][Full Text] [Related]
17. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy.
Conaghan PG; Peterfy C; Olech E; Kaine J; Ridley D; Dicarlo J; Friedman J; Devenport J; Troum O
Ann Rheum Dis; 2014 May; 73(5):810-6. PubMed ID: 24525910
[TBL] [Abstract][Full Text] [Related]
18. Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study.
Mori S; Yoshitama T; Abe Y; Hidaka T; Hirakata N; Aoyagi K; Ueki Y
Rheumatology (Oxford); 2019 Jul; 58(7):1274-1284. PubMed ID: 30793749
[TBL] [Abstract][Full Text] [Related]
19. Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.
Kojima T; Yabe Y; Kaneko A; Takahashi N; Funahashi K; Kato D; Hanabayashi M; Asai S; Hirabara S; Asai N; Hirano Y; Hayashi M; Miyake H; Kojima M; Ishiguro N
Rheumatology (Oxford); 2015 Jan; 54(1):113-20. PubMed ID: 25102861
[TBL] [Abstract][Full Text] [Related]
20. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY).
Dougados M; Kissel K; Sheeran T; Tak PP; Conaghan PG; Mola EM; Schett G; Amital H; Navarro-Sarabia F; Hou A; Bernasconi C; Huizinga TW
Ann Rheum Dis; 2013 Jan; 72(1):43-50. PubMed ID: 22562983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
